AVPT vs NVDA

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite solid revenue growth (23.6% YoY) and strong gross margins (74.51%), profitability remains thin with only a 0.50% net margin and weak ROE (0.67%). Analysts recommend a 'buy' with a $19.02 target, implying 51% upside, but insider selling of $89.11M over the last six months contradicts this optimism. The stock trades at a high forward P/E of 32.18, above sector averages, while recent price performance is bearish (-31.3% over 1Y), reflecting market skepticism despite improving earnings trends.

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.